Condition: Ductal Carcinoma in Situ · Extensive Disease · Mastectomy · Sponsor: Institut Cancerologie de l'Ouest
Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most often manifest as diffuse microcalcifications. This mutilating surgical management contrasts with the excellent prognosis of this pathology and considerably alters the quality of life of patients. Neoadjuvant hormone therapy has shown its efficacy in hormone-dependent infiltrating ductal carcinomas and offers the possibility of conservative surgery after hormone therapy. Adjuvant hormone therapy with Tamoxifen or anti-aromatase drugs has shown its efficacy in the prevention of homo or contralateral recurrence. The HORNEO 01 trial fits perfectly in the current context of surgical de-escalation of ductal carcinomas in situ. The objective of the study is to evaluate the impact of neoadjuvant hormone therapy on the surgical management of extensive DCIS.
This description comes directly from the study's public registry record.
Victoire BRILLAUD-MEFLAH, MD · 0240679818 · Victoire.brillaud-meflah@ico.unicancer.fr
Emilie DEBEAUPUIS · 0240679844 · emilie.debeaupuis@ico.unicancer.fr
Always discuss trial participation with your own doctor first.
| ICO - Site Paul Papin | Angers, France | Recruiting |
| Institut Bergonie | Bordeaux, France | Recruiting |
| Institut de cancérologie de Montpellier | Montpellier, France | Recruiting |
| Centre Antoine Lacassagne | Nice, France | Recruiting |
| Institut Curie - Site de Paris | Paris, France | Not Yet Recruiting |
| Hopital Saint Joseph | Paris, France | Recruiting |
| Institut de Cancérologie de l'Ouest | Saint-Herblain, France | Recruiting |
| IUCT-O | Toulouse, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04666961